Last update 25 Feb 2026

CLG-561

Overview

Basic Info

Drug Type
Biological products
Synonyms
NOV-7
Target
properdin
Action
inhibitors
Mechanism
properdin inhibitors(complement factor properdin inhibitors)
Therapeutic Areas
Congenital DisordersEye Diseases
Active Indication-
Inactive Indication
Age Related Macular DegenerationGeographic Atrophy
Originator Organization
MorphoSys AGMorphoSys AG
Active Organization-
Inactive Organization
Alcon Research Ltd.Novartis Institutes for BioMedical Research GmbH & Co. KG
License Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with CLG-561
NCT02515942
/ CompletedPhase 2
A Randomized, Multi-Center, Single Masked, Sham Controlled, Proof-of-Concept Study of Intravitreal CLG561 as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy
NCT01835015
/ CompletedPhase 1
A Multi-Center, Open-Label, Single Ascending Dose Study To Assess the Safety, Tolerability, and Serum Pharmacokinetics of Intravitreal CLG561 in Subjects With Advanced Age-Related Macular Degeneration
100 Clinical Results associated with CLG-561
Login to view more data
100 Translational Medicine associated with CLG-561
Login to view more data
100 Patents (Medical) associated with CLG-561
Login to view more data
100 Deals associated with CLG-561
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Geographic AtrophyPhase 2-
Alcon Research Ltd.
25 Sep 2015
Geographic AtrophyPhase 2-
Novartis Institutes for BioMedical Research GmbH & Co. KG
25 Sep 2015
Age Related Macular DegenerationPhase 1-
Alcon Research Ltd.
01 May 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT02515942 (CTgov)
Phase 2
Geographic Atrophy
114
(CLG561)
vbvstclmld = pnnlivheck auegjizpap (obplldkugh, kjaafhshtw - wkepsvxtnt)
View more
-
19 Dec 2018
(CLG561+LFG316)
vbvstclmld = rziyajemnw auegjizpap (obplldkugh, wuqtjrvgmk - dtnabaeozw)
View more
ARVO2016
Phase 2
Age Related Macular Degeneration
-
xnjfihcqch(orkiqatulf) = qvfotrpdnl kougbmwwef (pnuruabmqs )
View more
-
01 May 2016
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free